Journal Article

DZNE-2026-00995

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine.

Scheuble, J. ; Zeyen, T. ; Schneider, M. ; Potthoff, A.-L. ; Schäfer, N. ; Lex, L. ; Friker, L. L. ; Radbruch, A.DZNE* ; Layer, J. P. ; Gkika, E. ; Vatter, H. ; Herrlinger, U. ; Weller, J.

2026
Springer Science + Business Media B.V Dordrecht [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1007/s11060-026-05813-y

Abstract: Blood group O has recently been associated with improved survival in patients with MGMT-methylated glioblastoma. However, whether this association persists in patients treated with intensified first-line radiochemotherapy according to the CeTeG/NOA-09 regimen remains unclear. We aimed to validate the prognostic impact of ABO blood group in an independent cohort of patients with MGMT-methylated, IDH-wildtype glioblastoma uniformly treated with CCNU/temozolomide (CCNU/TMZ).We performed a retrospective single-center cohort study including adult patients with newly diagnosed MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG/NOA-09 protocol between 2008 and 2023. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates, log-rank tests, and multivariable Cox proportional hazards models adjusted for age, extent of resection, and Karnofsky Performance Status.Sixty-one patients were included, of whom 24 (39.3%) had blood group O and 37 (60.7%) had non-O blood groups. Blood group O was associated with longer OS (median 42.1 vs. 23.7 months; log-rank p = 0.04) and a trend toward longer PFS (median 21.8 vs. 17.5 months; log-rank p = 0.10). After multivariable adjustment, non-O blood groups remained independently associated with shorter PFS (HR 1.86, 95% CI 1.04-3.34; p = 0.037) and OS (HR 2.29, 95% CI 1.16-4.52; p = 0.017).Blood group O remained associated with improved progression-free and overall survival in patients with MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG/NOA-09 regimen. These findings support an association between blood group O and improved survival outcomes and warrant further investigation of its biological and clinical relevance in glioblastoma.

Keyword(s): Humans (MeSH) ; Temozolomide: administration & dosage (MeSH) ; Glioblastoma: therapy (MeSH) ; Glioblastoma: blood (MeSH) ; Glioblastoma: pathology (MeSH) ; Female (MeSH) ; Tumor Suppressor Proteins: genetics (MeSH) ; Male (MeSH) ; Brain Neoplasms: therapy (MeSH) ; Brain Neoplasms: blood (MeSH) ; Brain Neoplasms: pathology (MeSH) ; Prognosis (MeSH) ; Middle Aged (MeSH) ; DNA Modification Methylases: genetics (MeSH) ; DNA Modification Methylases: metabolism (MeSH) ; Retrospective Studies (MeSH) ; Lomustine: administration & dosage (MeSH) ; DNA Repair Enzymes: genetics (MeSH) ; Chemoradiotherapy: mortality (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Antineoplastic Combined Chemotherapy Protocols: therapeutic use (MeSH) ; DNA Methylation (MeSH) ; Follow-Up Studies (MeSH) ; ABO blood group ; Glioblastoma ; Lomustine ; MGMT promoter methylation ; Temozolomide ; Temozolomide ; Tumor Suppressor Proteins ; DNA Modification Methylases ; MGMT protein, human ; Lomustine ; DNA Repair Enzymes

---

Contributing Institute(s):

1. Clinical Neuroimaging (AG Radbruch)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2026

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---